



부광약품 오픈이노베이션 성과 및 전략 발표회

부광약품 자회사
콘테라파마의 파이프라인 및
룬드벡(Lundbeck)과 체결한
RNA 플랫폼 기술 소개



CONTERA PHARMA



- 
1. 인사말 - 부광약품 이제영 CEO
 2. 콘테라파마 소개 - 콘테라파마 토마스 세이거 CEO
 3. 부광약품 소개 - 부광약품 안미정 회장
(BK 신약 개발 전략 및 비전)
 4. Q&A 세션
- 



CONTERA PHARMA

Unlocking Science. Changing Lives.

Contera Pharma A/S
Venlighedsvej 4, 2970 Hørsholm
DK – Denmark
write: info@conterapharma.com; visit: www.conterapharma.com

Two core drivers for continuity and growth

CP-012



Parkinson's Disease

- **Commitment to improve treatment of movement disorders**
- Apply relevant internal/external data on **existing therapeutic knowledge** to **unlock** new potential
- **CP-012** represents a novel clinical asset with low biological risk
- Accelerated development path **towards PoC in Ph II**

RNA



RNA Therapeutics

- **Commitment to disorders arising from genetic causes or with a strong genetic link**
- **Unlock** the potential of next generation RNA therapeutics
- Founded in our **AttackPoint® discovery** and through **OligoDisc®** and **SpliceMatrix®** designed to deliver oligonucleotide or small molecule pipeline candidates
- **Attractive expansion potential:** Platform technology allows to operate on targets in various tissues / organs (therapy area agnostic)

Contera Pharma drug discovery facilities


650m² state-of-the-art laboratories

CONTERA PHARMA

Well equipped for drug discovery (platform and compound identification)



Compound/Oligo management, cell lab., iPSCs, cell-based assay, HTP RNA purification, cells & tissue, QPCR, Digital PCR, RNAseq, protein analysis: capillary electrophoresis



CONTERA PHARMA

26+ years of experience in
CNS pharma – research
leadership, BD & corporate
strategy



17+ years neurology R&D,
regulatory, BD & corporate
strategy



13+ years of pharma finance,
accounting and planning +
corporate strategy and BD
valuations



15+ years of drug development experience from pharma and biotech



- 15+ yrs of CNS drug discovery
- 10+ ASO patents
- Technical project lead for several oligo CNS programs, including rugonersen



- 10+ yrs in RNA therapeutics drug discovery
- 15+ patents in ASOs and RNA therapeutics
- Innovation lead in ASO technology



- 10+ yrs of oligo drug discovery
- 30+ patents and scientific papers on ASOs
- RNA tx design lead at Roche, member of OSWG* off-target sub committee



- 10+ yrs in oligo drug discovery
- Multiple ASO patents and publications
- Project lead for several ASO CNS programs



6

Scientific Advisors & Board of Directors

SCIENTIFIC ADVISORY BOARD



Christoph Rosenbohm, PhD

Seasoned life science executive & entrepreneur

CMC regulatory considerations for oligonucleotide drug products



Kenneth S. Loveday, PhD

Consultant for biopharmaceutical industry

Oligonucleotide and regulatory toxicology



Rene Holm, PhD

Professor, University of Southern Denmark

Drug formulation and product development



Mikael Thomsen, PhD

Co-founder, expert drug developer, seasoned biotech entrepreneur

Early pharmaceutical development



Morten Jørgensen, PhD

Med. Chem. specialist, Leo Pharma Biotech drug discovery advisor

Medicinal chemistry, early drug discovery



BOARD OF DIRECTORS



Woo Hyun Lee

Chair of the Board

Chairman of OCI Holdings



Mi-Chung Ahn

Director

Chairman of Bukwang Pharmaceutical



Jaeyoung Lee

Director

CEO of Bukwang Pharmaceutical



Mahmoud Mahmoudian, FRS

Director

Chief Biotech Investment Officer, Summit Impact Partners



Paul E.G. Kristjansen, MD, PhD, and DMSc

Director

Senior Scientific Director at The Lundbeck Foundation



Thomas Sager, PhD

Director

CEO, Contera Pharma

Diversified portfolio

Ph II ready asset and emerging RNA pipeline of first-in-class small molecules and oligonucleotides



PARKINSON'S DISEASE FRANCHISE

Project	Mechanism	Indication	Discovery	In vivo PoC	Preclinical	Phase I	Phase II	Partner
CP-012 (SMOL)	Fixed dose combination	Morning OFF in Parkinson's disease						In-house*

RNA FRANCHISE

CP-102 (ASO)	RNA silencing	Canavan disease						In-house
CP-101 (ASO)	RNA silencing	Metachromatic leukodystrophy						In-house
CP-107 (ASO)	Undisclosed	FCCM						In-house
CP-108 (ASO/SMOL)	Undisclosed	Amyotrophic lateral sclerosis+						In-house
Partnered								
Two programs	Undisclosed	Neurology						


*License to formulation technology with BDD Pharma, UK

SMOL: small molecule; FCCM: Familial cerebral cavernous malformations

Early morning off is a yet unresolved medical challenge in Parkinson's Disease

Nocturnal Immobility and Early Morning OFF in Parkinson's Disease

- **Nocturnal immobility:** Problems turning in bed and going to the toilet at night, leading to pain and decreased sleep quality
- **Early Morning OFF:** Following awakening in the morning, patients suffer from OFF and a delayed "ON" until the first dose of Levodopa reaches an effective plasma level, resulting in pain and immobility in the morning. Strongly affects Quality of Life as well as resulting in occurrence of non-motor symptoms



Prevalence

- **50-70% of all PD patients** experience at least one of the two symptoms above
- **Majority suffering from both** nocturnal akinesia and EMO
- Prevalence, especially of EMO, increases with **overall PD severity duration on Levodopa treatment** and **cumulative Levodopa dose**



Management


- **Short acting rescue formulations** taken during the night
- **Devices continuously releasing Levodopa** are often **inconvenient** for patients and **increase cumulative Levodopa dose**
- **DBS** - primarily reserved for patients with **very severe PD**

Unique profile with high commercial potential differentiated from other levodopa/carbidopa products

CONTERA PHARMA

No currently available levodopa products addresses morning OFF*


Current data supports a product with significant commercial potential



Favorable risk profile (PK/PD, mechanistic and regulatory)



Unique position to get a **new, world first, label for morning OFF**



Growing Parkinson's disease market ~7% CAGR to 2033#




USD 900m+ peak sales opportunity**

*No product with label specifically focused on alleviating morning OFF


**Supported by external market research

GlobalData report 5 Aug 2025: Parkinson's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Identification of attack points guides discovery of novel RNA modifiers



Using unique platforms, we identify RNA regions well suited to molecular intervention and evaluate multiple modalities and chemistries at scale to develop ideal RNA-based corrective therapeutics



Contera Pharma's RNA platform has broad relevance for discovery of innovative & competitive RNA-targeting medicines



What value does Contera Pharma's RNA platform deliver?

- ✓ Proprietary platform to discover imperfections in RNA processing
- ✓ Identifies position for ASOs and sMOL (targets-within-targets). Down or up-regulation
- ✓ Applicable to any tissue, organ and therapeutic area

AttackPoint Discovery®


- ✓ Fast discovery to lead selection
- ✓ Machine learning assisted design
- ✓ High potency and selectivity leading to high therapeutic index

OligoDisc®

- ✓ sMOL screening platform agnostic to specific RNA processing mechanisms
- ✓ Multiplexed assays focused on qualified AttackPoints across several targets

SpliceMatrix®

Contera Pharma platform has distinct position in the space of RNA therapeutics



CONTERA PHARMA



- ## First-in-class pipeline & attractive platforms

- ## Commercial outlook

- *MLD: Metachromatic leukodystrophy; ALS: Amyotrophic lateral sclerosis; FCCM: Familial cerebral cavernous malformations

Strategic collaboration with H. Lundbeck A/S to discover and advance RNA-targeting medicines in neuroscience



news.cision.com / H. Lundbeck A/S / Lundbeck and Contera Pharma an...

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions

MON, OCT 20, 2025 09:00 CET

Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical needs remain.

Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative benefits for patients worldwide. The partnership will leverage Lundbeck's more than 70 years of neuroscience experience and Contera Pharma's oligonucleotide expertise and pioneering proprietary RNA discovery platforms, including AttackPoint discovery®, OligoDisc®, and SpliceMatrix®.

"Partnering with Contera provides us with the opportunity to expand our pipeline with RNA-targeting candidates that can result in entirely new treatments. The collaboration perfectly supports our aim to deliver therapies for patients with serious neurological conditions where few or no options exist today."

Tarek Samad
Senior Vice President & Head of Research at Lundbeck

Charl van Zyl • 1st
President & CEO – Lundbeck | Pharma & Biotech Leader Driving Transformation

Brain health is one of the greatest challenges of our time. No one can solve it alone. Speeding up neuroscience innovation requires partnerships that push boundaries and make the impossible possible.

That's why I am proud to share that **Lundbeck** is entering new strategic research collaboration with **Contera Pharma** to advance RNA-targeting medicines for neurological conditions. Together we are expanding our research pipeline and broadening our scientific capabilities – driving R&D forward where transformative breakthroughs are most needed.

Contera Pharma
3,796 followers
3w •

Exciting news 🌟🧬🧪 : Contera Pharma and H. Lundbeck A/S are joining forces to discover RNA-targeting medicines for severe neurological disorders — combining Contera's cutting-edge, innovative RNA platform with Lundbeck's leadin ...more

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for...
conterapharma.com

Thomas Sager • 1st
Chief Executive Officer at Contera Pharma | Leadership | Strategy | R&D | Busi...

We are thrilled to announce that Contera Pharma and H. Lundbeck A/S have entered into a research collaboration agreement focused on discovering novel treatments for serious neurological disorders through Contera Pharma's cutting-edge RNA technology platform.

This partnership will combine the complementary strengths of Contera Pharma's deep expertise in RNA biology with H. Lundbeck A/S's industry-leading knowledge in CNS drug discovery — driving innovation to future treatment options. The agreement represents a strong validation of our RNA platform and aligns with our strategic ambition to create meaningful impact — both through the advancement of our internal pipeline and by pursuing high-value collaborations — all with the shared goal of identifying new treatment opportunities for patients living with serious medical conditions.

Contera Pharma
3,796 followers
3w •

Exciting news 🌟🧬🧪 : Contera Pharma and H. Lundbeck A/S are joining forces to discover RNA-targeting medicines for severe neurological disorders — combining Contera's cutting-edge, innovative RNA platform with Lundbeck's leading neuroscience expertise to advance transformative new therapies.

Strategic collaboration with H. Lundbeck A/S to discover and advance RNA-targeting medicines in neuroscience



External validation of Contera's leading RNA platform technology



- **Lundbeck:** Global biopharmaceutical company with 70+ years in neuroscience research & development, ~5,700 employees in 50+ countries, developing treatments for neurological and psychiatric diseases, with products available in 80+ countries.



- **Contera:** Applies proprietary RNA platforms (AttackPoint® discovery & OligoDisc®) to drive drug discovery



- **Collaboration** is a joint discovery preclinical development of novel oligonucleotide-based therapies – Lundbeck funds all research activities and retains development and commercialization option




- **Deal:** Upfront payment + research funding, preclinical-, clinical-, and commercial milestones and tiered royalties on future sales*

Combining Contera's RNA discovery engine with Lundbeck's neuroscience expertise to deliver **first-in-class RNA targeting medicines** addressing high unmet need in brain health

Executing on strategy to increase pipeline and technology value

Key strategic goals

-  **CP-012 phII PoC**
Progress key pipeline assets (CP-10X)
Expand beyond CNS
-  **Consolidate SpliceMatrix**
-  **Deals (collaborations / out-licensing)**





CONTERA PHARMA

Unlocking Science. Changing Lives.

Contacts:

Thomas Sager, CEO (ts@conterapharma.com)

Anders Brandt Elvang, COO (ae@conterapharma.com)

Contera Pharma A/S
Venlighedsvej 4, 2970 Hørsholm
DK – Denmark

write: info@conterapharma.com; visit: www.conterapharma.com

BK 신약 개발 전략 및 비전

"Global Open Innovation Hub"


2025. 11. 18

부광약품
회장 안 미 정



BK의 혁신 신약 R&D 및 투자 History

지난 10여 년간 BK의 신약 개발 활동은 **해외 Open Innovation**에 집중



전략 1 | 기존 해외 R&D 및 투자 자산에 대한 **선택과 집중** 전략

BUKWANG PHARM. CO., LTD.

CONTERA PHARMA

지난 10년간 확보한 파이프라인과 플랫폼 기술을 재평가하여 육성·협업 등 후속 전략방안 마련

1

Contera CP-012 (파킨슨병)

혁신 치료제의 신속한 2상 진입 추진

- 성공적 1b상 개발을 기반으로 임상 2상 진입 가속화
- 단독 개발, 공동개발, 라이선스 아웃 등 다양한 전략적 옵션 검토

2

Contera RNA 신약 플랫폼

RNA 플랫폼기반 신규 자회사 설립

- RNA 신약 플랫폼의 대외적 경쟁력 입증
- RNA 플랫폼 전문 신규 자회사 설립

3

JaguAhr & Protekt

효율화 전략 방안 마련

- 연구 결과·시장성·회사 전략 방향성과의 적합성을 철저히 검토하여 향후 진행방향 결정 (추가투자·파트너링·투자 중단 등)

➔ 글로벌 자산의 가치를 극대화·효율화하기 위한 **선택과 집중** 전략을 단계적으로 실행

전략 2 | 신규 해외 Open Innovation 확대 전략

BUKWANG PHARM. CO., LTD.

CONTERA PHARMA

차세대 바이오 모달리티 재발굴 및 AI-바이오 혁신기술에 대한 확장 모색

BK/OCIH 직접투자 회사



BK 간접투자 회사 (TVM 펀드)



글로벌 AI·바이오 펀드 참여 검토

Global AI기반 바이오 인큐베이셔널 펀드 SUMMIT IMPACT PARTNERS

- AI·바이오 융합 혁신에 집중하는 벤처 인큐베이터 기반 펀드 참여 검토
- 현재 1차 ~\$50m 규모, 향후 \$300m 규모로 확대 예정
- The Colorado Health & Tech Centers에서 벤처 인큐베이터 설립하며 현재 6개 AI 바이오기업 투자



Modality/기술 분류별 기업 현황



차세대 바이오 모달리티·플랫폼 기술 보유회사 중심 투자대상 재발굴



신규 해외 Open Innovation 추진

AI혁신 바이오기술에 대한 접근성 확보



글로벌 AI-바이오 융합 Open Innovation 기회 발굴

전략 3 | 국내 Open Innovation 활성화 전략

BUKWANG PHARM. CO., LTD.

CONTERA PHARMA

국내 유망기술 발굴과 바이오 펀드 조성을 통해 기술 내재화 및 차세대 성장 기반 확보

1 국내 Open Innovation 적극 추진

국내 유망 초기 바이오 기술·벤처 발굴 및 내재화 추진

- 국내 유망 바이오 벤처 기술 검토 중
(그 간 약 30개사 이상 검토)
- 현재 5개 국내 대학·연구소의 유망
기술/특허 검토 중
- 국내 펀드에 참여하여 오가노이드 기업에
간접 투자 완료
(CCGI 펀드 통해 Curi Bio 간접투자)



2 BK중심의 신규 바이오 펀드 조성

BK의 3대 타겟을 중심으로 바이오 펀드를 이용해 국내
혁신 기술에 대한 접근성 확대

- BK 3대 투자 타겟;
 - 바이오 플랫폼 혁신 기술
 - CNS 관련 혁신 기술
 - AI-바이오 기반 혁신 기술




Full 밸류체인 전략

“유망기술 발굴 → 전략적 협업 / 투자 → M&A 등 내재화”

BK Vision: “Global Open Innovation Hub”

국내 혁신기술과 글로벌 네트워크를 연결하는 **혁신 신약개발 Open Innovation hub** 역할 수행

BK 글로벌 바이오 생태계 구축



Thank you!